←
Ocular Therapeutix961 posts
Ocular Therapeutix avatar

Ocular Therapeutix

@OCUTX

Ocular Therapeutix, Inc. is a biopharmaceutical company committed to redefining the retina experience across drug development, treatment, and outcomes.

◷ Joined November 2016▧ 899 Photos and videos
Ocular Therapeutix avatar
Ocular Therapeutix@OCUTX·Feb 17

Today, we announced positive results from the landmark SOL-1 Phase 3 superiority trial in wet AMD, an important step forward as we aim to reduce the treatment burden, with the data presentation taking place at Macula Society this month. Learn more: ow.ly/svKn50YgYXM

0:10
Ocular Therapeutix avatar
Ocular Therapeutix@OCUTX·Nov 6

Time between injections is only part of how retina specialists judge durability in wet age-related macular degeneration (AMD). At #AAO2026, four told us what else they weigh, from sustained vision and fluid control to safety and consistency over time. #RetinaOnRecord

1:34
Ocular Therapeutix avatar
Ocular Therapeutix@OCUTX·Oct 30

Sawtooth. Seesaw. Different ways to describe fluid that comes and goes between treatments. At #AAO2026, we spoke with retina specialists about how they consider this pattern when evaluating long-term control of wet AMD.​ ​ #RetinaOnRecord #RetinaRedefined

1:34
Ocular Therapeutix avatar
Ocular Therapeutix@OCUTX·Oct 28

For many people with #WetAMD, staying on therapy means frequent injection visits, often with a caregiver’s support. At @RetinaSociety, we asked what happens when that schedule becomes difficult to sustain, and what it can mean for vision over time.​ ​ #RetinaOnRecord

1:36
Ocular Therapeutix avatar
Ocular Therapeutix@OCUTX·Oct 23

What does long-term success in wet age-related macular degeneration (AMD) look like? At #AAO2026, we sat down with a group of retina specialists to explore their perspectives on disease control and the importance of maintenance over time.​ ​ #RetinaOnRecord #RetinaRedefined

1:33
Ocular Therapeutix avatar
Ocular Therapeutix@OCUTX·Aug 7

Retina specialists shared how filing based on a single Phase 3 clinical trial may help new treatment options reach patients sooner at @asrsdocs. Insights like these highlight the importance of our work to advance innovation for patients.​ Learn more: ow.ly/i13Q50ZvbsS

1:07
Ocular Therapeutix avatar
Ocular Therapeutix@OCUTX·Aug 3

Today we shared Q2 2026 earnings and new data on what durability could mean for people with wet AMD. We also remain on track for an AMD NDA submission in Q4 2026 following a positive FDA Type C meeting. ​ ​ Learn more: bit.ly/4w9a5gf ​ $OCUL #RetinaRedefined

Post attachment